IP Library Granted Patent US 7,341,837
Granted Patent B2
US 7,341,837 · App. 10/653,321 · Granted Mar 11, 2008

Soluble analyte detection and amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,341,837
App. No.
10/653,321
Granted
Mar 11, 2008
Kind
B2
Abstract

The present invention relates to a method of detection of a compound of interest that is present at low levels in a sample. In particular, the present invention relates to a method of detection of a compound of interest in solution by a nucleic acid-labelled binding construct, separation of the unbound nucleic acid-labelled binding construct, and the detection of the bound nucleic acid-labelled binding construct in the solution phase. The present invention is particularly adaptable to be used in conjunction with a nucleic acid amplification reaction for detecting the presence or absence of the nucleic acid portion of binding construct in a sample indicating the presence or absence of the compound of interest.

Claims (50)

1. A method for detecting a non-nucleic acid compound of interest in a biological or environmental sample comprising the steps of:

a) providing a binding construct comprising an antibody or an antibody fragment portion which specifically recognizes and specifically binds said non-nucleic acid compound of interest without capture on a solid support, and a nucleic acid portion;

b) mixing said binding construct with said biological or environmental sample in a solution mixture to form construct-compound complexes in solution without capture on a solid support, wherein said non-nucleic acid compound of interest in said biological or environmental sample becomes specifically bound to said binding construct;

c) providing one or more surfaces, wherein said surfaces bear one or more accessible non-nucleic acid binding targets capable of specifically recognizing and specifically binding to said antibody or said antibody fragment portion of said binding construct;

d) introducing said one or more surfaces to said solution mixture of said construct-compound complexes after said non-nucleic acid compound of interest in said biological or environmental sample has become bound to said binding construct in order for said one or more surfaces to form construct-surface complexes in solution with any unbound binding constructs resulting in said solution mixture containing essentially said construct-compound complexes and said construct-surface complexes;

e) separating said construct-surface complexes from said solution mixture leaving behind said construct-compound complexes in solution; and

f) detecting the presence or absence of said nucleic acid portion of said construct-compound complexes in solution after said separation step (e), said detection being done without the presence of any of said surfaces in connection with said construct-compound complexes that are being detected;

wherein the presence of said nucleic acid portion of said construct-compound complexes indicates the presence of said non-nucleic acid compound of interest in said biological or environmental sample.

2. The method of claim 1 , wherein said one or more surfaces is selected from the group consisting of: particles, powders, beads, planar surfaces, non-planar surfaces, a tube, a well, non-porous films, non-porous membranes, porous films, porous membranes, fibers, fillers, meshes, grids, filters, matrices, gels, and combinations thereof.

3. The method of claim 1 , wherein said one or more surfaces comprise particles.

4. The method of claim 3 , wherein said particles comprise magnetic particles.

5. The method of claim 4 , wherein said step (e) comprises separating said construct-surface complexes out of said mixture by means of a magnet.

6. The method of claim 5 , wherein, in step (f), said detecting the presence or absence of said nucleic acid portion of said binding construct comprises amplification of said nucleic acid portion.

7. The method of claim 6 , wherein said amplification of said nucleic acid portion comprises a polymerase chain reaction.

8. The method of claim 1 , wherein, in step (f), said detecting the presence or absence of said nucleic acid portion of said binding construct comprises amplification of said nucleic acid portion.

9. The method of claim 8 , wherein said amplification of said nucleic acid portion comprises a polymerase chain reaction.

10. The method of claim 1 , wherein said antibody or antibody fragment portion comprises a single chain antibody variable region fragment.

11. The method of claim 1 , wherein said antibody or antibody fragment portion comprises a Fab fragment.

12. The method of claim 11 , wherein said Fab fragment is attached to said nucleic acid portion through the free sulfhydryl of the Fab fragment.

13. The method of claim 1 , wherein said nucleic acid portion comprises DNA.

14. The method of claim 1 , wherein said nucleic acid portion comprises RNA.

15. The method of claim 1 , wherein said nucleic acid portion comprises a nucleic sequence that does not include a sequence that is expected to be found in the biological or environmental sample.

16. The method of claim 1 , wherein said step (a) comprises providing two or more different types of binding constructs, wherein each of said two or more different binding constructs has a different antibody or antibody fragment portion and a different nucleic acid portion.

17. A method for solution-phase detection of a non-nucleic acid compound of interest, comprising the steps of:

a) providing a biological or environmental sample suspected of containing said non-nucleic acid compound of interest;

b) providing a binding construct comprising:

i) an antibody or an antibody fragment portion capable of specifically binding said non-nucleic acid compound of interest without capture on a solid support, and

ii) a nucleic acid portion

c) contacting said biological or environmental sample with said binding construct for a period of time sufficient to permit said antibody or antibody fragment portion to specifically bind said non-nucleic acid compound of interest present in said biological or environmental sample, thereby forming construct-compound complexes in solution, wherein said non-nucleic acid compound of interest in said biological or environmental sample becomes specifically bound to said binding construct;

d) providing one or more surfaces, wherein said one or more surfaces bears one or more accessible non-nucleic acid binding targets capable of specifically binding to said antibody or antibody fragment portion;

e) contacting said one or more surfaces with said solution alter said non-nucleic acid compound of interest in said biological or environmental sample has become bound to said binding construct for a period of time sufficient for said one or more accessible non-nucleic acid binding targets to specifically bind said antibody or antibody fragment portion of any binding construct not bound to said non-nucleic acid compound of interest, thereby forming construct-surface complexes in said solution resulting in said solution containing essentially said construct-compound complexes and said construct-surface complexes;

f) separating said construct-surface complexes from said solution, leaving said construct-compound complexes in said solution; and

g) detecting the presence or absence of said nucleic acid portion of said construct-compound complexes in said solution after said separation step (f), said detection being done without the presence of any said surfaces in connection with said construct-compound complexes that are being detected;

wherein said separation of said construct-surface complexes from said solution results in a separation of all binding constructs not bound to a non-nucleic acid compound of interest, and

wherein the presence of said nucleic acid portion of said construct-compound complexes indicates the presence of said non-nucleic acid compound of interest in said biological or environmental sample.

18. The method of claim 17 , wherein said one or more surfaces is selected from the group consisting of: particles, powders, beads, planar surfaces, non-planar surfaces, a tube, a well, non-porous films, non-porous membranes, porous films, porous membranes, fibers, fillers, meshes, grids, filters, matrices, gels, and combinations thereof.

19. The method of claim 17 , wherein said one or more surfaces comprise particles.

20. The method of claim 19 , wherein said particles comprise magnetic particles.

21. The method of claim 20 , wherein said step (f) comprises separating substantially all said construct-surface complexes from said solution by means of a magnet.

22. The method of claim 21 , wherein, in step (g), said detecting the presence or absence of said nucleic acid portion of said binding construct comprises amplification of said nucleic acid portion.

23. The method of claim 22 , wherein said amplification of said nucleic acid portion comprises a polymerase chain reaction.

24. The method of claim 17 , wherein, in step (g), said detecting the presence or absence of said nucleic acid portion of said binding construct comprises amplification of said nucleic acid portion.

25. The method of claim 24 , wherein said amplification of said nucleic acid portion comprises a polymerase chain reaction.

26. The method of claim 17 , wherein said antibody or antibody fragment portion comprises a single chain antibody variable region fragment.

27. The method of claim 17 , wherein said antibody or antibody fragment portion comprises a Fab fragment.

28. The method of claim 27 , wherein said Fab fragment is attached to said nucleic acid portion through the free sulfhydryl of the Fab fragment.

29. The method of claim 17 , wherein said nucleic acid portion comprises DNA.

30. The method of claim 17 , wherein said nucleic acid portion comprises RNA.

31. The method of claim 17 , wherein said nucleic acid portion comprises a nucleic sequence that does not include a sequence that is expected to be found in said biological or environmental sample.

32. The method of claim 17 , wherein said step (b) comprises providing two or more different types of binding constructs, wherein each of said two or more different binding constructs has a different antibody or antibody fragment portion and a different nucleic acid portion.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2012
From: NEW ENGLAND RARE REAGENTS, LLC
To: RESTALYST PTE LTD
Reel/Frame 028978/0346 →
NUNC PRO TUNC ASSIGNMENT Recorded Jun 21, 2010
From: NEW ENGLAND RARE REAGENTS, INC
To: NEW ENGLAND RARE REAGENTS, LLC
Reel/Frame 024563/0460 →
SECURITY AGREEMENT Recorded Dec 18, 2009
From: RESTALYST PTE LTD
To: NEW ENGLAND RARE REAGENTS, LLC
Reel/Frame 023668/0501 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2009
From: NEW ENGLAND RARE REAGENTS, LLC
To: RESTALYST PTE LTD
Reel/Frame 023627/0671 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2009
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: BINAX, INC.
Reel/Frame 023538/0244 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2009
From: GENERAL ELECTRIC CAPITAL CORPORATION, AGENT
To: BINAX, INC.
Reel/Frame 023525/0410 →
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 27, 2007
From: IM US HOLDINGS, LLC, A DELAWARE LIMITED LIABILITY COMPANY; INVERNESS MEDICAL INNOVATIONS, INC., A DELAWARE CORPORATION; ADVANTAGE DIAGNOSTICS CORPORATION, A DELAWARE CORPORATION; APPLIED BIOTECH, INC., A CALIFORNIA CORPORATION; BINAX, INC., A DELAWARE CORPORATION; FIRST CHECK DIAGNOSTICS CORP., A DELAWARE CORPORATION; FOREFRONT DIAGNOSTICS, INC., A CALIFORNIA CORPORATION; INCA ACQUISITION, INC., A DELAWARE CORPORATION; INNOVATIVE MOBILITY, LLC, A FLORIDA LIMITED LIABILITY COMPANY; INSTANT TECHNOLOGIES, INC., A VIRGINIA CORPORATION; INVERNESS MEDICAL - BIOSTAR, INC., A DELAWARE CORPORATION; INVERNESS MEDICAL INTERNATIONAL HOLDING CORP., A DELAWARE CORPORATION; INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II, A DELAWARE CORPORATION; INNOVATIONS RESEARCH, LLC, A DELAWARE LIMITED LIABILITY COMPANY; INVERNESS MEDICAL, LLC, A DELAWARE LIMITED LIABILITY COMPANY; ISCHEMIA TECHNOLOGIES, INC., A DELAWARE CORPORATION; IVC INDUSTRIES, INC., A DELAWARE CORPORATION; INNOVACON, INC., A DELAWARE CORPORATION; OSTEX INTERNATIONAL, INC., A WASHINGTON CORPORATION; QUALITY ASSURED SERVICES, INC., A FLORIDA CORPORATION; SELFCARE TECHNOLOGY, INC., A DELAWARE CORPORATION; SPDH, INC., A DELAWARE CORPORATION; UNIPATH ONLINE, INC., A MASSACHUSETTS CORPORATION; WAMPOLE LABORATORIES, LLC, A DELAWARE LIMITED LIABILITY COMPANY
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 019477/0808 →
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 26, 2007
From: IM US HOLDINGS, LLC, A DELAWARE LIMITED LIABILITY COMPANY; INVERNESS MEDICAL INNOVATIONS, INC., A DELAWARE CORPORATION; ADVANTAGE DIAGNOSTICS CORPORATION, A DELAWARE CORPORATION; APPLIED BIOTECH, INC., A CALIFORNIA CORPORATION; BINAX, INC., A DELAWARE CORPORATION; FIRST CHECK DIAGNOSTICS CORP., A DELAWARE CORPORATION; FOREFRONT DIAGNOSTICS, INC., A CALIFORNIA CORPORATION; INCA ACQUISITION, INC., A DELAWARE CORPORATION; INNOVATIVE MOBILITY, LLC, A FLORIDA LIMITED LIABILITY COMPANY; INSTANT TECHNOLOGIES, INC., A VIRGINIA CORPORATION; INVERNESS MEDICAL - BIOSTAR, INC., A DELAWARE CORPORATION; INVERNESS MEDICAL INTERNATIONAL HOLDING CORP., A DELAWARE CORPORATION; INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II, A DELAWARE CORPORATION; INNOVATIONS RESEARCH, LLC, A DELAWARE LIMITED LIABILITY COMPANY; INVERNESS MEDICAL, LLC, A DELAWARE LIMITED LIABILITY COMPANY; ISCHEMIA TECHNOLOGIES, INC., A DELAWARE CORPORATION; IVC INDUSTRIES, INC., A DELAWARE CORPORATION; INNOVACON, INC., A DELAWARE CORPORATION; OSTEX INTERNATIONAL, INC., A WASHINGTON CORPORATION; SELFCARE TECHNOLOGY, INC., A DELAWARE CORPORATION; SPDH, INC., A DELAWARE CORPORATION; UNIPATH ONLINE, INC., A MASSACHUSETTS CORPORATION; QUALITY ASSURED SERVICES, INC., A FLORIDA CORPORATION
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 019477/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2006
From: LAWTON, ROBERT L.
To: NEW ENGLAND RARE REAGENTS, INC.
Reel/Frame 017271/0856 →
Continuity (1)
Related Publication 20050048500A1 · Mar 3, 2005